Typical Atrial Flutter Clinical Trial
— AcQForce AFLOfficial title:
AcQBlate Force Sensing Ablation System US IDE for Atrial Flutter (AcQForce Flutter)
Verified date | September 2023 |
Source | Acutus Medical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Acutus Medical AcQForce Flutter clinical study is a prospective, multi-center, non-randomized global study designed to demonstrate the safety and effectiveness of the AcQBlate Force Sensing Ablation System in the ablation management of symptomatic cavotricuspid isthmus dependent atrial flutter.
Status | Completed |
Enrollment | 115 |
Est. completion date | June 12, 2022 |
Est. primary completion date | May 12, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subjects are clinically indicated for de novo catheter ablation of typical atrial flutter. 2. At least one (1) documented episode of typical atrial flutter within 180 days (6 months) prior to enrollment, documented by 12-lead ECG. 3. Age 18 years or older at time of consent. 4. Subjects are willing and able to provide written informed consent to participate in the study and agree to comply with all follow-up visits and evaluations. Exclusion Criteria: 1. In the opinion of the Investigator, any contraindication to the planned atrial ablation, including contraindications to anticoagulation therapy and any other significant uncontrolled or unstable medical condition (e.g. sepsis, acute metabolic illness, chronic kidney disease). 2. Inability to entrain CTI dependent AFL by standard pacing at procedure. 3. Any prior right atrial cavotricuspid isthmus ablation. 4. Any cardiac ablation for non-atrial flutter arrhythmias within 90 days prior to enrollment. 5. Any patient scheduled or anticipating an AF ablation within the follow-up period. 6. Use of amiodarone within 120 days prior to procedure. 7. Cardiac surgery within 60 days prior to enrollment. 8. ST-elevation myocardial infarction (STEMI) within 60 days prior to enrollment 9. Current unstable angina. 10. Documented atrial or ventricular tumors, clots, thrombus, within 30-days prior to enrollment. 11. Any history of a known hematologic disorder (bleeding/clotting). 12. Implantation of permanent leads of an implantable device in or through the right atrium within 90-days prior to enrollment. 13. Subjects with New York Heart Association (NYHA) Class IV heart failure within 6-months prior to enrollment. 14. Subjects with an ejection fraction less than 30% within 90 days of enrollment. 15. Percutaneous Transluminal Coronary Angioplasty (PTCA) within 30-days of enrollment. 16. Clinically significant structural heart disease (including moderate to severe tricuspid valve regurgitation, tricuspid valve stenosis, or tricuspid valve replacement; Ebstein's anomaly, or other congenital heart disease) that would preclude catheter introduction and placement, as determined by the Investigator. 17. Any cerebral ischemic/infarct event (excluding transient ischemic attacks) within 180 days prior to enrollment. 18. Body Mass Index (BMI) >42 kg/m2. 19. International Normalized Ratio (INR) > 3. 20. Severe uncontrolled systemic hypertension (systolic pressure > 240 mm Hg) within the last 30-days. 21. Women who are pregnant or plan to become pregnant within the course of their participation in the investigation. 22. Current enrollment in any other study protocol where testing or results from the study may interfere with the procedure or outcome measurements for this study. 23. Any other condition that, in the judgment of the Investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center). |
Country | Name | City | State |
---|---|---|---|
Belgium | ZNA Middelheim | Antwerpen | |
Belgium | Jessa Ziekenhuis | Hasselt | |
United Kingdom | James Cook University Hospital | Middlesbrough | |
United Kingdom | Freeman Hospital | Newcastle Upon Tyne | |
United States | St Alphonsus Health System | Boise | Idaho |
United States | BayCare Heath | Clearwater | Florida |
United States | Ohio State Med Ctr | Columbus | Ohio |
United States | John Muir Health | Concord | California |
United States | Hartford Hospital | Hartford | Connecticut |
United States | Penn State Health | Hershey | Pennsylvania |
United States | MedStar Health Research Institute | Hyattsville | Maryland |
United States | Arrhythmia Research Group | Jonesboro | Arkansas |
United States | Lancaster General Hospital | Lancaster | Pennsylvania |
United States | Baptist Lexington Medical Center | Lexington | Kentucky |
United States | Weill Cornell | New York | New York |
United States | Celebration Hospital | Orlando | Florida |
United States | Kansas City Heart Rhythm Institute | Overland Park | Kansas |
United States | Presbyterian Medical Center | Philadelphia | Pennsylvania |
United States | AZ Cardiovascular Research Center | Phoenix | Arizona |
United States | Bayfront Health | Saint Petersburg | Florida |
United States | San Diego Cardiac Center Medical Group, Inc. | San Diego | California |
United States | Adventist Healthcare | White Oak Medical Center | Silver Spring | Maryland |
United States | Adventist Healthcare, Inc | Silver Spring | Maryland |
United States | ProMedica Physician Cardiology | Toledo | Ohio |
Lead Sponsor | Collaborator |
---|---|
Acutus Medical |
United States, Belgium, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjects Free From Procedure/Device Related Serious Adverse Events (SAEs) | Subjects free from a composite list of pre-specified procedure/device related Serious Adverse Events (SAEs) | 7 days | |
Primary | Subjects Achieving Acute Procedural Success | Acute procedural success is defined as the demonstration of bidirectional cavotricuspid isthmus block at least 20 minutes following the last radiofrequency application at the cavotricuspid isthmus with the investigational System. | 20 minutes post ablation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04434599 -
Fluoroscopic, Contact Force and Local Impedance With Ultra-high Density Mapping Guided Radiofrequency Ablation Comparison for cavoTricuspid Isthmus dependenT Atrial fluttER: the FLUTTER Study
|
N/A | |
Recruiting |
NCT05777850 -
High-Power Short-Duration Radiofrequency Ablation in Patients With Typical Atrial Flutter
|
N/A | |
Completed |
NCT01401361 -
Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System
|
Phase 3 | |
Completed |
NCT00984204 -
Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)
|
Phase 3 | |
Withdrawn |
NCT01710150 -
Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter
|
N/A | |
Completed |
NCT01408485 -
Therapy™ Cool Flex™ Irrigated Ablation System for Typical Atrial Flutter
|
N/A | |
Recruiting |
NCT00750711 -
Typical Flutter Ablation:A Comparison of 4 mm Versus 2 mm Irrigated cathéters
|
N/A | |
Recruiting |
NCT03867266 -
Typical Atrial Flutter, Ablation Index and Point by Point Ablation
|
||
Not yet recruiting |
NCT06157437 -
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Typical Atrial Flutter
|
N/A | |
Recruiting |
NCT04657055 -
AcQBlate Force Sensing Ablation System EU Study for Atrial Flutter (AcQForce Flutter-EU)
|
N/A |